CR11659A - Inhibidores de hsp90 - Google Patents
Inhibidores de hsp90Info
- Publication number
- CR11659A CR11659A CR11659A CR11659A CR11659A CR 11659 A CR11659 A CR 11659A CR 11659 A CR11659 A CR 11659A CR 11659 A CR11659 A CR 11659A CR 11659 A CR11659 A CR 11659A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- hsp90 inhibitors
- relates
- methods
- kits
- Prior art date
Links
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 101710113864 Heat shock protein 90 Proteins 0.000 abstract 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2572508P | 2008-02-01 | 2008-02-01 | |
| US10159508P | 2008-09-30 | 2008-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR11659A true CR11659A (es) | 2010-12-15 |
Family
ID=40436400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR11659A CR11659A (es) | 2008-02-01 | 2010-08-30 | Inhibidores de hsp90 |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US20110053873A1 (enExample) |
| EP (1) | EP2252595B1 (enExample) |
| JP (1) | JP5524084B2 (enExample) |
| KR (1) | KR20100116206A (enExample) |
| CN (1) | CN101983191B (enExample) |
| AR (1) | AR071452A1 (enExample) |
| AU (1) | AU2009208947B2 (enExample) |
| BR (1) | BRPI0906598A2 (enExample) |
| CA (1) | CA2713658C (enExample) |
| CL (1) | CL2009000228A1 (enExample) |
| CR (1) | CR11659A (enExample) |
| DO (1) | DOP2010000236A (enExample) |
| EA (1) | EA019156B1 (enExample) |
| EC (1) | ECSP10010434A (enExample) |
| ES (1) | ES2475206T3 (enExample) |
| GE (1) | GEP20125718B (enExample) |
| IL (1) | IL207227A0 (enExample) |
| MA (1) | MA32104B1 (enExample) |
| MX (1) | MX2010008269A (enExample) |
| MY (1) | MY150596A (enExample) |
| NZ (1) | NZ587207A (enExample) |
| PE (1) | PE20091371A1 (enExample) |
| SG (1) | SG187502A1 (enExample) |
| TW (1) | TW200946531A (enExample) |
| WO (1) | WO2009097578A1 (enExample) |
| ZA (1) | ZA201005435B (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2537898T3 (es) | 2005-10-25 | 2015-06-15 | Shionogi & Co., Ltd. | Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1 |
| AR061185A1 (es) | 2006-05-26 | 2008-08-13 | Chugai Pharmaceutical Co Ltd | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. |
| PE20090110A1 (es) | 2007-03-01 | 2009-04-04 | Chugai Pharmaceutical Co Ltd | Compuestos macrociclicos derivados de amina como agentes inhibidores de hsp90 |
| AU2008245082B8 (en) | 2007-04-24 | 2012-09-13 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| GB2449293A (en) * | 2007-05-17 | 2008-11-19 | Evotec | Compounds having Hsp90 inhibitory activity |
| WO2009097578A1 (en) * | 2008-02-01 | 2009-08-06 | Takeda Pharmaceutical Company Limited | Oxim derivatives as hsp90 inhibitors |
| US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
| WO2010047372A1 (ja) | 2008-10-22 | 2010-04-29 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害活性を有する２－アミノピリミジン－４－オンおよび２－アミノピリジン誘導体 |
| RU2012129168A (ru) | 2009-12-11 | 2014-01-20 | Сионоги Энд Ко. Лтд. | Производные оксазина |
| CA2816285A1 (en) | 2010-10-29 | 2012-05-03 | Shionogi & Co., Ltd. | Naphthyridine derivative |
| US9018219B2 (en) | 2010-10-29 | 2015-04-28 | Shionogi & Co., Ltd. | Fused aminodihydropyrimidine derivative |
| WO2012147763A1 (ja) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤 |
| ITTO20111013A1 (it) | 2011-11-03 | 2013-05-04 | Dac Srl | Composti farmaceutici |
| US20130210785A1 (en) | 2012-02-15 | 2013-08-15 | Emory University | Progesterone analogs and uses related thereto |
| JP2016501827A (ja) | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
| WO2014107655A1 (en) * | 2013-01-07 | 2014-07-10 | St. Jude Children's Research Hospital | Use of small molecule unfolder protein response modulators to treat tumors with active sonic hedgehog (ssh) signaling due to smoothened (smo) mutation |
| WO2014144715A1 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Hsp90-targeted cardiac imaging and therapy |
| WO2015023593A1 (en) | 2013-08-12 | 2015-02-19 | Emory University | Progesterone phosphate analogs and uses related thereto |
| EP3194975A4 (en) | 2014-09-17 | 2018-05-02 | Memorial Sloan Kettering Cancer Center | Hsp90-targeted inflammation and infection imaging and therapy |
| US9868738B2 (en) | 2014-09-19 | 2018-01-16 | Merck Sharp & Dohme Corp. | Diazine-fused amidines as BACE inhibitors, compositions, and their use |
| SG10201900628RA (en) | 2016-04-07 | 2019-02-27 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| WO2018200534A1 (en) * | 2017-04-24 | 2018-11-01 | Samus Therapeutics, Inc. | Hsp90 inhibitor oral formulations and related methods |
| EP3630291B9 (en) | 2017-05-26 | 2024-05-29 | Cancer Research Technology Limited | Benzimidazolone derived inhibitors of bcl6 |
| EP4324460A3 (en) | 2017-09-15 | 2024-04-24 | Dyve Biosciences, Inc. | Sodium bicarbonate for use in the treatment of gout and related disorders |
| US20190134219A1 (en) * | 2017-09-15 | 2019-05-09 | Ampersand Biopharmaceuticals, Inc. | Inhibition of spontaneous metastasis via protein inhibitors of cysteine proteases |
| IL296734B2 (en) | 2018-04-13 | 2025-06-01 | The Institute Of Cancer Res Royal Cancer Hospital | Bcl6 inhibitors |
| MX2025007723A (es) | 2018-05-14 | 2025-08-01 | Reata Pharmaceuticals Inc | Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor |
| GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
| CN112568223B (zh) * | 2020-04-13 | 2023-04-21 | 辽宁先达农业科学有限公司 | 除草组合物及其应用和除草剂 |
| CN111671749A (zh) * | 2020-06-12 | 2020-09-18 | 重庆医科大学 | 双香豆素在制备HBx蛋白稳定性抑制剂中的用途 |
| CN112661668B (zh) * | 2020-12-31 | 2023-07-28 | 辽宁先达农业科学有限公司 | 一种n-取代酰胺类化合物及其制备方法 |
| CN114259564B (zh) * | 2021-11-30 | 2023-03-14 | 清华大学 | Hsp90抑制剂阻碍stat3线粒体转运和治疗哮喘的新应用 |
| CN115073458A (zh) * | 2022-07-04 | 2022-09-20 | 山东致泰医药技术有限公司 | 一种阿维巴坦钠的制备方法 |
| CN115381816A (zh) * | 2022-08-04 | 2022-11-25 | 武汉市金银潭医院(武汉市传染病医院) | Ver50589在制备抗肠道病毒71型药物中的应用 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN117907491B (zh) * | 2024-03-12 | 2024-06-04 | 中国人民解放军军事科学院军事医学研究院 | 基于双衍生化技术的脱碱基位点lc-ms/ms分析方法 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA762455A (en) | 1962-03-22 | 1967-07-04 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | Pyrido-pyrimidines |
| DE1197466B (de) | 1962-03-22 | 1965-07-29 | Thomae Gmbh Dr K | Verfahren zur Herstellung von neuen 5, 6, 7, 8-Tetrahydropyrido-[4, 3-d]pyrimidinen |
| GB8912336D0 (en) | 1989-05-30 | 1989-07-12 | Smithkline Beckman Intercredit | Compounds |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| JP2000038350A (ja) | 1998-05-18 | 2000-02-08 | Yoshitomi Pharmaceut Ind Ltd | 糖尿病治療薬 |
| DE69939168D1 (de) | 1998-05-26 | 2008-09-04 | Warner Lambert Co | Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| EP1267876A1 (en) * | 2000-03-23 | 2003-01-02 | Merck & Co., Inc. | Thrombin inhibitors |
| WO2001070269A1 (en) | 2000-03-24 | 2001-09-27 | Akzo Nobel N.V. | Keratinocyte growth inhibitors and hydroxamic acid derivatives |
| US6946456B2 (en) | 2000-07-28 | 2005-09-20 | Sloan-Kettering Institute For Cancer Research | Methods for treating cell proliferative disorders and viral infections |
| JPWO2002015925A1 (ja) | 2000-08-22 | 2004-07-08 | 協和醗酵工業株式会社 | アポトーシスの制御方法およびアポトーシス制御ポリペプチド |
| US7439359B2 (en) * | 2000-11-02 | 2008-10-21 | Sloan-Kettering Institute For Cancer Research | Small molecule compositions for binding to hsp90 |
| CA2440809A1 (en) | 2001-03-01 | 2002-09-12 | Conforma Therapeutics Corp. | Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors |
| KR20020089883A (ko) | 2001-05-25 | 2002-11-30 | 주식회사 지인텍 | 마사지 장치 |
| EE200400042A (et) * | 2001-06-28 | 2004-10-15 | Essential Therapeutics, Inc. | 8/17 heterotsüklilised ühendid ning nende kasutamine D-alanüül-D-alaniini ligaasi inhibiitoritena |
| JP2005139066A (ja) * | 2001-12-14 | 2005-06-02 | Hsp Research Institute Inc | ２、３−ジヒドロ−１ｈ−キノリン−４−オンオキシム誘導体および熱ショック蛋白質発現誘導阻害剤 |
| JPWO2003068776A1 (ja) | 2002-02-15 | 2005-06-02 | 協和醗酵工業株式会社 | ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体 |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| AU2003229305A1 (en) | 2002-05-17 | 2003-12-02 | Scios, Inc. | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS |
| AU2003282512A1 (en) | 2002-10-22 | 2004-05-13 | The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services | Methods of reducing the activity of and reducing the concentration of a mutant kit protein |
| EP1457499A1 (en) | 2003-03-12 | 2004-09-15 | Tufts University School Of Medicine | Inhibitors of extracellular Hsp90 |
| US20050020534A1 (en) | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites |
| JPWO2005018674A1 (ja) | 2003-08-22 | 2006-10-19 | 協和醗酵工業株式会社 | イムノグロブリン遺伝子の転座を伴う疾患の治療薬 |
| ATE433974T1 (de) | 2003-09-19 | 2009-07-15 | Gilead Sciences Inc | Azachinolinolphosphonatverbindungen als integraseinhibitoren |
| WO2005070929A1 (en) | 2004-01-23 | 2005-08-04 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| TW200538120A (en) | 2004-02-20 | 2005-12-01 | Kirin Brewery | Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same |
| DE102004041163A1 (de) | 2004-08-25 | 2006-03-02 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
| WO2006050333A2 (en) | 2004-11-02 | 2006-05-11 | The Regents Of The University Of California | Methods and compositions for modulating apoptosis |
| BRPI0517268A (pt) | 2004-11-02 | 2008-10-07 | Conforma Therapeutics Corp | método para tratar uma forma de leucemia linfocìtica crÈnica |
| US20080193932A1 (en) | 2004-11-05 | 2008-08-14 | University Of Rochester | Methods Of Inhibiting the Activity of Hsp90 and/or Aryl Hydrocarbon Receptor |
| WO2006078891A2 (en) | 2005-01-21 | 2006-07-27 | Neurogen Corporation | Imidazolylmethyl and pyrazolylmethyl heteroaryl derivatives |
| WO2006083979A2 (en) | 2005-02-02 | 2006-08-10 | Nexgenix Pharmaceuticals, L.L.C. | Local treatment of neurofibromas |
| EP1865775A1 (en) | 2005-04-06 | 2007-12-19 | Irm, Llc | Diarylamine-containing compounds and compositions, and their use as modulators of steroid hormone nuclear receptors |
| US20070027150A1 (en) * | 2005-04-14 | 2007-02-01 | Bellamacina Cornelia R | 2-Amino-quinazolin-5-ones |
| JP5198256B2 (ja) | 2005-05-04 | 2013-05-15 | エボテク エージー | 縮合複素環式化合物、並びにそれらの組成物及び使用 |
| WO2006124904A2 (en) | 2005-05-16 | 2006-11-23 | Geron Corporation | Cancer treatment by combined inhibition of telomerase and hsp90 activities |
| US8722708B2 (en) | 2005-06-14 | 2014-05-13 | Merck Sharp & Dohme Inc. | Substituted isoindolines as aspartyl protease inhibitors |
| US20070105874A1 (en) | 2005-09-23 | 2007-05-10 | Conforma Therapeutics Corporation | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors |
| JO2783B1 (en) * | 2005-09-30 | 2014-03-15 | نوفارتيس ايه جي | Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones |
| WO2007082131A1 (en) | 2006-01-09 | 2007-07-19 | Bristol-Myers Squibb Company | Process for the preparation of hydroxy substituted heterocycles |
| US7851468B2 (en) | 2006-05-15 | 2010-12-14 | Cephalon, Inc. | Substituted pyrazolo[3,4-d]pyrimidines |
| EP2019677B1 (en) | 2006-05-16 | 2013-08-14 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| US8034834B2 (en) | 2006-05-25 | 2011-10-11 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders with HSP90 inhibitors |
| WO2007143629A1 (en) | 2006-06-02 | 2007-12-13 | Nexgenix Pharmaceuticals | Treatment of neurofibromatosis with inhibitors of a signal transduction pathway |
| JP5415942B2 (ja) | 2006-06-22 | 2014-02-12 | プラナ バイオテクノロジー リミティッド | 処置の方法およびその処置に有用な薬剤 |
| US20080160520A1 (en) * | 2006-06-22 | 2008-07-03 | Angelika Amon | Methods and Composition for Diagnosing and Treating Cancer |
| WO2008021981A2 (en) | 2006-08-09 | 2008-02-21 | Nexgenix Pharmaceuticals, Llc. | Local treatment of epidermal and dermal hyperproliferative lesions |
| WO2008045529A1 (en) | 2006-10-12 | 2008-04-17 | Serenex, Inc. | Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases |
| AU2007319209B2 (en) | 2006-11-15 | 2012-04-19 | Genentech, Inc. | Arylsulfonamide compounds |
| WO2008116216A1 (en) | 2007-03-22 | 2008-09-25 | Medical College Of Georgia Research Institute, Inc. | Compositions and methods for inhibiting cancer metastasis |
| GB2449293A (en) * | 2007-05-17 | 2008-11-19 | Evotec | Compounds having Hsp90 inhibitory activity |
| US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
| WO2009097578A1 (en) * | 2008-02-01 | 2009-08-06 | Takeda Pharmaceutical Company Limited | Oxim derivatives as hsp90 inhibitors |
-
2009
- 2009-01-30 WO PCT/US2009/032728 patent/WO2009097578A1/en not_active Ceased
- 2009-01-30 JP JP2010545233A patent/JP5524084B2/ja not_active Expired - Fee Related
- 2009-01-30 NZ NZ587207A patent/NZ587207A/en not_active IP Right Cessation
- 2009-01-30 KR KR1020107019568A patent/KR20100116206A/ko not_active Abandoned
- 2009-01-30 US US12/865,713 patent/US20110053873A1/en not_active Abandoned
- 2009-01-30 CN CN2009801117170A patent/CN101983191B/zh not_active Expired - Fee Related
- 2009-01-30 CA CA2713658A patent/CA2713658C/en not_active Expired - Fee Related
- 2009-01-30 MX MX2010008269A patent/MX2010008269A/es active IP Right Grant
- 2009-01-30 GE GEAP200911937A patent/GEP20125718B/en unknown
- 2009-01-30 ES ES09706850.6T patent/ES2475206T3/es active Active
- 2009-01-30 AU AU2009208947A patent/AU2009208947B2/en not_active Expired - Fee Related
- 2009-01-30 EA EA201070912A patent/EA019156B1/ru not_active IP Right Cessation
- 2009-01-30 BR BRPI0906598-9A patent/BRPI0906598A2/pt not_active IP Right Cessation
- 2009-01-30 SG SG2013004676A patent/SG187502A1/en unknown
- 2009-01-30 EP EP09706850.6A patent/EP2252595B1/en active Active
- 2009-01-30 MY MYPI20103648 patent/MY150596A/en unknown
- 2009-01-30 US US12/363,640 patent/US8071766B2/en not_active Expired - Fee Related
- 2009-02-02 CL CL2009000228A patent/CL2009000228A1/es unknown
- 2009-02-02 AR ARP090100342A patent/AR071452A1/es not_active Application Discontinuation
- 2009-02-02 PE PE2009000150A patent/PE20091371A1/es not_active Application Discontinuation
- 2009-02-02 TW TW098103333A patent/TW200946531A/zh unknown
-
2010
- 2010-07-26 IL IL207227A patent/IL207227A0/en unknown
- 2010-07-29 ZA ZA2010/05435A patent/ZA201005435B/en unknown
- 2010-07-30 DO DO2010000236A patent/DOP2010000236A/es unknown
- 2010-08-26 MA MA33117A patent/MA32104B1/fr unknown
- 2010-08-30 EC EC2010010434A patent/ECSP10010434A/es unknown
- 2010-08-30 CR CR11659A patent/CR11659A/es not_active Application Discontinuation
-
2011
- 2011-10-11 US US13/271,134 patent/US8618290B2/en not_active Expired - Fee Related
-
2012
- 2012-03-01 US US13/410,045 patent/US20120172321A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP10010434A (es) | Inhibidores de hsp90 | |
| ECSP10010688A (es) | Activadores de glucoquinasa | |
| CY1121744T1 (el) | Παραγωγα c4-μονομεθυλο-τριτερπενοειδους και μεθοδοι χρησης αυτων | |
| CR20110135A (es) | INHIBIDORES DE cMET | |
| ECSP11010798A (es) | 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa | |
| CR11427A (es) | 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa | |
| UY32863A (es) | COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR | |
| UY32077A (es) | Inhibidores de quinasa tipo polo | |
| CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
| UY31705A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| ECSP10010129A (es) | Inhibidores de quinasas símil polo | |
| SV2010003617A (es) | Fungicidas | |
| CO6311105A2 (es) | Derivados sinteticos de producto natural con propiedades anti-inflamatorias | |
| CO6450612A2 (es) | Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750 | |
| CR20110028A (es) | Derivados de pirimidina como inhibidores de cinasa | |
| PY1332818A (es) | Composiciones fungicidas | |
| UY32723A (es) | Compuestos de triazol que portan un sustituyente de azufre x | |
| UY32724A (es) | Compuestos de triazol que portan un sustituyente de azufre xi | |
| UY32553A (es) | Nuevos derivados de la pirrolidinadiona espiroheterocíclicos 3-sustituidos | |
| CR10304A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
| CR9684A (es) | Nuevos derivados de la benzoheterocicliletil carboxamida | |
| CU20090064A7 (es) | Nuevos derivados de benzamida como antagonistas de la bradiquinina | |
| CO6361849A2 (es) | Derivados de n-cicloalquil-nbifenilmetil-carboxamida fungicidas | |
| NI201100139A (es) | Microbiocidas nuevos. | |
| UY32667A (es) | Nuevos derivados de furano espiroheterocíclico y tiofuranodiona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |